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The	 European	 commission	 defines	 personalised	medicine	 as	 a	medical	 approach	
that	uses	molecular	insights	into	health	and	disease	brought	on	by	the	sequencing	of	
the	 genome	 to	 guide	 decision-making	 with	 regard	 to	 the	 prediction,	 prevention,	











known	 in	 our	 society,	 the	 objective	 of	 this	 project	 is	 to	 try	 to	 understand	 the	
underlying	 mechanisms	 of	 cystic	 fibrosis	 disease	 and	 shed	 light	 on	 what	 makes	






que	 utilitza	 els	 coneixements	moleculars	 de	 salut	 i	malaltia	 obtinguts	 a	 travès	 de	 la	
seqüenciació	 del	 genoma	 per	 guiar	 la	 presa	 de	 decisions	 pel	 que	 fa	 a	 la	 predicció,	
prevenció,	diagnòstic	 i	 tractament	de	malalties.	El	seu	objectiu	principal	generalment	





els	 principis	 de	 la	 medicina	 personalitzada	 a	 Amèrica.	 En	 el	 seu	 discurs,	 va	 utilitzar	




Atès	 al	 gran	 ressò	 mediàtic	 que	 l’Ivacaftor	 va	 assolir	 i	 la	 gran	 desconeixença	 de	 la	
societat	 sobre	 la	 fibrosis	 quística,	 l’objectiu	 d’aquest	 treball	 ha	 estat	 conèixer	 la	









throughout	 the	 degree	 with	 different	 pharmaceutical	 knowledge	 areas.	 This	 project	
has	 been	 supervised	 by	 the	 Biochemistry	 and	Molecular	 Biology	 unit,	 which	mainly	
focuses	 on	 the	 study	 of	 the	 structure	 and	 function	 of	 naturally	 occuring	




of	 this	 project.	 Consequently,	 the	 project	 will	 explore,	 from	 a	 biomolecular	
perspective,	 cystic	 fibrosis	 patophysiology	 and	 diagnosis	 as	 an	 example	 of	 applied	
personalised	medicine	in	modern	healthcare.	
	




Lastly	but	not	 leastly,	 the	birth	of	personalised	medicine	 cannot	be	 fully	understood	
without	 the	 recent	 technological	 advancements	 in	 the	 field	 of	 genomics	 and	
bioinformatics.	 For	 this	 reason,	 I	 will	 keep	 track	 of	 these	 recent	 technological	 leaps	
that	have	helped	shape	nowadays	personalised	medicine	approach.	
	
In	summary,	 the	effort	done	 in	 integrating	the	above	mentioned	areas	of	knowledge	
will	help	make	possible	 the	achievement	of	 the	main	objective	of	 the	project,	which	
was	 	gaining	an	 insight	 into	the	potential	benefits	of	personalised	medicine,	not	only	
from	 a	 genomic	 understanding,	 but	 also	 in	 the	 fields	 of	 drug	 therapy	 and	 the	

















According	 to	 the	 European	 Commission,	 personalised	 medicine	 refers	 to	 a	 medical	
approach	 that	 uses	 molecular	 insights	 into	 health	 and	 disease	 brought	 on	 by	 the	
sequencing	 of	 the	 genome	 to	 guide	 decision-making	 with	 regard	 to	 the	 prediction,	
prevention,	diagnosis	and	treatment	of	illnesses.	It’s	main	aim	is	generally	perceived	to	
be	 “the	 right	 treatment	 for	 the	 right	 person	 at	 the	 right	 time”(1).	 This	 translates	 in	
offering	 care	 based	 both	 on	 current	 evidence	 and	 patients	 unique	 background	
characteristics	to	enable	proper	predictions	of	their	clinical	outcome.	
	
Everyone	 is	 interested	 in	 the	 idea	 that	 their	medicine	should	be	personalized.	But	 in	
fact,	the	idea	that	we	should	take	care	of	patients	in	a	highly-individualized	way	is	not	
something	new.	Back	 in	ancient	Greece,	Hippocrates	 is	quoted	 for	 saying	“It	 is	more	
important	 to	 know	what	 sort	 of	 person	 has	 a	 disease	 than	 to	 know	what	 sort	 of	 a	
disease	a	person	has”(2).	In	other	words,	it's	more	important	understanding	patient’s	
background	before	trying	to	understand	his	disease.	More	recently,	Sir	William	Osler,	
considered	 by	many	 the	 founder	 of	modern	medicine,	 is	widely	 quoted	 for	 another	
remarkable	 statement	 “The	 good	 physician	 treats	 the	 disease.	 The	 great	 physician	
treats	the	patient	who	has	the	disease.”	Again,	great	physicians	understand	what	it	is	














The	 recent	 advancements	 in	 our	 disease	 understanding,	 inevitably	 results	 in	 the	
identification	 of	 differences	 across	 the	 same	 disease.	 In	 consequence,	 stratification	
into	 smaller	 subtypes	 of	 said	 disease	 usually	 takes	 place.	 However,	 classic	 drug	
development	has	always	been	about	the	performance	of	drugs	in	very	large	population	
samples.	This	approach,	 the	so	called	 the	“one	drugs	 fits	all”,	dismisses	 the	 inherent	
individual	variability	among	individuals	while	targeting	a	common	condition	that	hasn’t	








modern	 healthcare	 and	 the	 pharmaceutical	 industry	 is	 undergoing	 a	 radical	 shift	
towards	 a	more	 specific,	 tailored	 and	 patient	 driven	 drug	 development.	 In	 this	 new	
model,	 regulatory	 agencies	 no	 longer	 focus	 drug	 evaluation	 solely	 in	 drug’s	 average	
efficacy	 and	 safety	 in	 a	 given	 population.	 Instead,	 they	 also	 search	 for	 resistant	





way	 to	 reach	 the	 ‘best’	 treatment	 for	 an	 irresponsive	 patient(3).	 This	methodology,	
frequently	 used	 while	 treating	 common	 multifactorial	 diseases	 such	 as	 diabetes,	
hypertension	 or	 depression,	 often	 leads	 to	 several	 inappropriate	 and	 ineffective	






100.000	 habitants(4),	 can	 give	 us	 a	 good	 idea	 of	 the	 importance	 of	 preventing	 such	
events	both	for	patients	well-being	and	for	healthcare	providers	budget.		
	
There	 are	 several	 confounding	 factors	 that	 can	 determine	whether	 a	 patient	will	 be	
responsive	 to	 a	 drug	 or	 suffer	 an	 adverse	 drug	 event.	 Just	 to	 name	 a	 phew:	 miss-
dosing,	 genetic	 background,	 drug	 interactions	 and	 allergies	 among	 others.	 Although	
this	may	be	 true,	 a	patient’s	 individual	 genetic	predisposition	 for	 inappropriate	drug	
response	remains	the	 least	studied	factor(5).	This	 is	surprising	because	provided	that	
it’s	 been	 well-documented,	 from	 as	 early	 as	 the	 90s,	 that	 in	 some	 cases,	




a	 given	 drug	 and	 identifying	 those	 at	 most	 risk	 to	 suffer	 an	 adverse	 drug	 event,	
















patient’s	 response	 is	a	much	deeper	understanding	of	genomics.	 From	1953	Watson	
and	 Crick’s	 outstanding	 discovery	 of	 DNA	 structure(9),	 we	 are	 now	 capable	 of	
sequencing	 a	 whole	 human	 genome	 in	 24	 hours	 for	 1500$(10).	 The	 recent	
advancement	 in	 next-generation	 sequencing	 (NGS)	 methods	 provide	 a	 cheap	 and	
reliable	 large-scale	sequencing	technology.	They	are	used	extensively	for	sequencing,	
disease	mapping,	SNP	tagging,	 to	quantify	expression	 levels	 through	RNA	sequencing	
and	 also	 in	 population	 genetic	 studies	 such	 as	 genome	 wide	 association	 studies	
(GWAS)	that	help	scientists	study	and	determine	genes	role	in	relation	to	disease(11).	
	
As	 demonstrated	 in	 figure	 3,	 these	 technologies	 are	 in	 continuous	 improvement.	 In	
fact,	 the	cost	per	Mb	of	data	has	decreased	tremendously,	 from	nearly	3000$/Mb	in	
the	first	platforms	towards	a	mere	amount	of	0.07$/Mb	in	the	platform	Ilumina	Hi-seq	
2000(12).	 It	 is	 theorized	 that	 this	 rate	of	acceleration	 in	 sequencing	output	 is	 clearly	
just	 beginning.	 Recent	 NGS	 platforms	 just	 introduced	 to	 the	 market	 will	 have	 a	
continuing	and	lasting	impact	on	biomedical	research	for	years	to	come.	As	technology	
advances,	current	 instruments	will	 continue	to	evolve,	at	a	 rate	even	 faster	 than	the	
rate	of	advancement	 in	computer	throughput	pedicted	by	Moore’s	 law	(10).	 In	other	





DNA	 sequences	 and	 understand	 how	 they	 should	 be	 applied	 to	 individual	 patients.	
Whereas	 in	 the	 past,	 in	 early	 Sanger’s	 sequencing	 times,	 when	 sequencing	 was	
extremely	 slow,	 sequence	 output	 was	 the	 true	 rate	 limiting	 in	 advancing	 biological	














































To	clarify,	 the	 revolution	 in	personalised	medicine	 is	mainly	 taking	advantage	of	 two	
developments,	 one	 in	 the	 science	 of	 genomics,	 with	 advancements	 in	 genetic	
technologies	 and	 techniques	 such	 as	 genotyping	 or	 microarrays,	 and	 the	 other,	 in	
bioinformatics,	with	advancements	in	algorithms,	huge	data	processing	and	even	deep	
machine	 learning.	 Both	 have	 been	 pillars	 and	 sources	 of	 information	 to	 effectively	
apply	 personalised	medicine.	 An	 important	 distinction	 to	 draw	 is	 that	 by	 huge	 data	
sets	we	are	not	 just	 limited	 to	molecular	DNA	sequencing	data,	but	also	many	other	
types	of	molecular	data,	ranging	from	epigenetics,	mRNA	expression,	metabolomics	or	
proteomics.	Another	equally	 important	 type	of	data	 is	 none	molecular	data,	 such	as	
the	information	contained	in	patient	record	files	or	from	patient’s	blood	analysis.		
	
All	 these	 sorts	 of	 data	 are	 what’s	 shaping	 modern	 bioinformatics	 and	 what	 makes	
feasible	the	current	personalised	medicine	approach.	In	the	future,	we	will	learn	more	
about	disease	 susceptibility	 and	drug	 response	by	 looking	 at	molecular	 data	 such	 as	
DNA	patterns	or	mRNA	expression	levels	combined	with	none	molecular	data	such	as	
patterns	in	electronic	medical	records	or	blood	samples	and	understand	what	it	is	that	
makes	an	 individual	or	 a	disease	 special.	 In	 this	 setting,	bioinformatics	purpose	 is	 to	
investigate	 those	 tremendously	 large	 data	 sets,	 analyse	 their	 interrelationships	 and	
extract	clinically	valuable	information	for	both	scientists	and	physicians.	
	
Therefore,	 personalised	 medicine	 seeks	 to	 move	 away	 from	 the	 classic	 heavily	
symptom-based	diagnostics	towards	a	model	where	molecular	characterisation	is	the	
main	indicator	of	disease	diagnosis	and	prognosis.	This	approach,	alternatively	known	
as	biomarkers	based	medicine,	 is	what	ultimately	will	 guide	and	 improve	physician’s	
decision	making	and	enable	a	true	individualisation	of	patients.		
Figure	3:	Changes	in	NGS	instrument	capability	over	the	past	decade	and	the	timing	of	major	sequencing	projects.	








considered	 to	 be	 mostly	 based	 on	
genomics	 and	 bioinformatics,	 it’s	 the	
result	 of	 a	 far	 more	 complex	 network	
from	 the	 combination	 of	 science,	
technology,	 engineering	 and	 medicine	
fields	(STEM)	as	shown	in	figure	4.				
	
In	 addition	 to	 the	 genes,	 several	 other	
factors	that	vary	among	individuals	can	
influence	 drug	 response	 or	 disease	
course,	and	 thus,	must	also	be	 studied	
and	 properly	 addressed.	 For	 instance,	
the	 characterization	 of	 the	 intestine	 flora,	 the	 microbiome,	 which	 has	 been	
demonstrated	 to	 interfere	 in	 drug	metabolism	 and	 to	 play	 a	 central	 role	 in	 human	
health,	 has	 the	potential	 to	help	determine	 current	patient	 immune	 status	 and	help	







state,	 can	 directly	 affect	 drugs	 half-life.	 Recently,	 chronoparmacokineticists	
demonstrated	 that	56	out	of	 the	100	best	 selling	drugs	 in	 the	US	 target	products	of	
genes	 in	 clinically	 relevant	 organs	 whose	 expression	 cycles	 significantly	 oscillate	





But	 besides	 the	 difficulties	 of	 the	 challenge	 of	 individualising	 healthcare,	 the	
implementation	of	this	new	approach	faces	many	other	problems	of	different	nature.	
What	many	healthcare	professionals	encounter	 in	 their	daily	practice	 is	 that	patients	
level	of	excitement	around	 the	concepts	of	personalised	medicine	vary	broadly.	 This	
happens	 for	many	 reasons	unrelated	 to	 their	 biological	 health,	 but	 rather	with	 their	
environment,	the	way	they	were	brought	up,	their	educational	level	and	their	religious	











Given	 these	 points,	 a	 more	 updated	 and	 mandatory	 health	 education	 should	 be	
encouraged(3).	We	should	promote	early	educational	campaigns	designed	to	facilitate	








of	 genetic	 testing	 in	 disease	 management	 (71%);	 problems	 such	 as	 lack	 of	 clinical	





the	 world	 are	 developing	 a	 range	 of	 different	
initiatives.	 Notable	 examples	 in	 Europe	 include	
EMA’s	development	of	Supplementary	Information	
S1,	 a	 regulatory	 framework	 aiming	 to	 harmonize,	
among	other	things,	current	biospecimen	sampling	








titled	 “Paving	 the	 way	 for	 personalised	medicine”	
outlined	 the	 steps	 the	 agency	 would	 take	 to	
integrate	 genetic	 and	 biomarker	 information,	 to	
develop	 a	 better	 regulatory	 science	 and	 to	 help	
advance	drug	development	(18).		
	
Moreover,	 back	 in	 2014,	 Obama’s	 administration	
launched	 the	 Precision	Medicine	 Initiative,	 shown	
in	 figure	 5,	 to	 accelerate	 biomedical	 research	 and	
provide	clinicians	with	new	tools	to	select	therapies	
that	 work	 best	 in	 individual	 patients	 with	 specific	
diseases(19).		






Semantically,	 both	 personalised	 medicine	 and	 precision	 medicine	 are	 often	 used	
interchangeably.	However,	 there	 is	 a	 concern	 that	 the	word	 "personalized"	 could	be	
misinterpreted	to	imply	that	treatments	and	preventions	are	being	developed	uniquely	
and	solely	for	each	individual	patient,	although	this	could	be	true	to	some	extent,	the	
precision	 medicine	 term	 focuses	 mainly	 on	 identifying	 which	 approaches	 will	 be	
effective	 for	 patients	 based	 on	 genetic,	 environmental	 and	 lifestyle	 factors(20).	 This	
distinction,	 coupled	 with	 the	 fact	 that	 precision	 medicine	 current	 definition	 among	
experts	is	generally	understood	as	an	approach	to	understand	disease	in	a	deeper	level	




an	example	of	 the	potential	benefits	of	 applying	precision	medicine	 towards	disease	




affects	many	 systems,	 including	 the	 gastrointestinal,	 reproductive	 and	 specially,	 the	
respiratory	 system.	 It	 is	 the	most	 common	 fatal	 genetic	 disorder,	most	 prevalent	 in	
caucasian	descent	population,	as	 shown	 in	 figure	6,	and	has	a	highly	variable	clinical	
presentation	 and	 course	 depending	 on	 specific	mutations,	 several	 genetic	modifiers	
and	environmental	factors.	Until	recently,	no	treatments	were	available	that	targeted	
the	 underlying	 cause	 of	 cystic	 fibrosis	 and	 consequently,	 all	 available	 treatment,	
consisting	 of	 preventive	 antibiotics,	 bronchodilators,	 mucus	 thinners,	 steroids	 and	














Luckily,	 this	all	 changed	with	 the	market	 launch	 in	2012	of	 Ivacaftor,	a	novel	 first-in-
class	 drug	 that	 specifically	 targets	 cystic	 fibrosis	 aetiology	 rather	 than	 symptoms.	 It	







The	 drug	 was	 discovered	 after	 decades	 of	 intense	 research	 after	 application	 of	
genomics	 in	 different	 stages	 of	 the	 drug	 development.	 After	 several	 collaborative	
projects	 between	 patients,	 scientists	 and	 the	 drug	 manufacturer,	 researchers	
investigating	CF	finally	understood,	at	a	molecular	level,	the	reasons	why	CFTR	fails	to	
function.	Based	on	this	knowledge,	 the	drug	manufacturer	designed	successful	cystic	
fibrosis	 in	 vitro	 models	 and	 via	 high-throughput	 screening	 identified	 a	 molecule	
capable	 of	 reverting	 this	 malfunction.	 Then,	 through	 iterative	 medicinal	 chemistry	
techniques,	the	manufacturer	developed	a	drug	capable	of	improving	CFTR	activity	in	a	
concrete	 subset	 of	 specific	 mutations(22).	 Shortly	 after,	 the	 developer	 of	 Ivacaftor	
designed	a	genetic	test	to	determine	patient’s	eligibility	for	treatment.	Without	delay,	





Another	 remarkable	 aspect	 in	 the	 drug	 development	 of	 Ivacaftor	 that	 sets	 it	 as	 the	
perfect	 example	 for	 future	 drug	 development	 is	 the	 path	 that	 ultimately	 led	 to	 the	
discovery	 of	 Ivacaftor	was	 remarkably	 patient	 driven.	 The	 drug	 itself	 came	 out	 of	 a	
collaboration	 between	 the	 drug’s	 manufacturer	 and	 the	 Cystic	 Fibrosis	 Foundation	
(CFF)(23).	 CFF	 has	 fought	 cystic	 fibrosis	 for	many	 years,	 organizing	 and	 coordinating	
the	patient	community	and	helping	fund	the	research	that	led	to	the	discovery	of	CFTR	
sequence	back	in	1989(24).	CFF	has	also	helped	in	the	establishment	of	a	large	public	
CF	patient	 registry	mutation	databank	 (Cystic	 Fibrosis	Mutation	Database)	 accessible	
for	free	for	researchers	all	over	the	world(25)	and	has	helped	establish	the	clinical	trial	
network	for	investigating	and	determining	the	genetics	of	the	disease	while	recruiting	
participants	 for	 testing	candidate	drugs	aswell(18).	The	 foundation	 itself	helped	 fund	
Ivacaftor	discovery	and	development	with	a	total	amount	of	75M$(26).		
	
Overall,	 the	 drug	 itself	 was	 such	 a	 breakthrough	 in	 both	 drug	 development	 and	 in	
cystic	fibrosis	clinical	management,	that	it	was	described	as	a	wonder	drug	among	the	
medical	 community	 and	 labelled	 as	 “The	 most	 important	 drug	 of	 2012”	 by	 Forbes	
magazine(27).		
	
All	 things	 considered,	 the	 special	 nature	 of	 cystic	 fibrosis	 disease,	 the	 amount	 of	
research	conducted	over	several	decades	and	the	singular	characteristics	of	 Ivacaftor	
development	make	 it	 a	 great	example	of	 the	 revolutionary	potential	 of	personalised	












encodes	 an	 epithelial	 ion	 channel	 known	 as	 the	 cystic	 fibrosis	 transmembrane	
conductance	 regulator	 (CFTR).	 The	 disease	 is	 transmitted	 in	 an	 autosomal	 recessive	






in	 several	 organs.	 Its	 impairment	 affects	 airways,	 sinuses,	 the	 intestinal	 tract,	 the	
genitourinary	 system,	 the	 pancreas	 and	 the	 biliary	 system.	 This	 leads	 to	 a	wide	 and	
variable	 array	 of	 clinical	 manifestations	 and	 complications,	 shown	 in	 figure	 7,	 the	




Although	 it	 has	been	 theorized	 that	 cystic	 fibrosis	has	been	around	 from	as	early	 as	
3000BC,	 it	was	 first	described	on	medical	 literature	by	Dr.	Hansine	 in	1936(28),	who	
first	linked	cystic	fibrosis	pancreatic	problems	with	abnormal	pulmonary	and	intestinal	
malfunction.	 She	 was	 the	 first	 physician	 to	 use	 pancreatic	 enzyme	 replacement	
therapy	to	treat	affected	children	and	established	the	first	cystic	fibrosis	diagnosis	test.	
When	CF	was	 first	described,	patient’s	 life	was	painful	and	short	as	 seen	 in	 figure	8.	
However,	 as	 pancreatic	 supplementation	 became	 widely	 available	 and	 preventive	
antibiotics	began	to	be	used,	coupled	with	an	improved	patient	care	and	nutrition,	the	
life	expectancy	and	quality	of	life	for	cystic	fibrosis	patients	increased	dramatically.		
Figure	 8:	 Growth	 in	 CF	 patient’s	 life	
expectancy	 in	 the	 last	century.	Reaching	
a	 total	 of	 32	 life	 years	 in	 2000,	 it’s	











One	 of	 the	most	 challenging	 problem	 in	 the	management	 of	 cystic	 fibrosis	 and	 the	
major	determinant	of	patient’s	quality	of	 life	and	 life	 span	 is	pulmonary	disease(31).	
Due	 to	CFTR	malfunction,	as	 shown	 in	 figure	9,	 the	 lack	of	 transport	of	 chloride	and	
excessive	 sodium	 reabsorption	 cause	 absorption	 of	 water	 via	 osmosis	 across	 all	
respiratory	tract	leading	to	a	dehydrated	airway	surface	fluid	and	impairing	mucociliary	
clearance.	Ultimately,	this	excessive	viscid	mucus	drastically	increases	the	incidence	of	
infections	 by	 the	 entrapment	 of	 bacteria	 in	 airway	 secretions	 and	 causes	 local	
inflammation	 in	 response(32).	 As	 a	 result,	 chronic	 lung	 infection	 incidence	 in	 cystic	
fibrosis	patients	is	high	and	steadily	increases	with	age	due	to	different	mechanisms.		
	
Firstly,	 bacterial	 adaptation	 to	 the	 airway	 environment	 ensues	 with	 a	 shift	 from	
planktonic	to	a	biofilm	mode	of	growth	by	pressure	selection	of	mutant	bacteria	with	
abundant	exopolysaccharide	production	capable	of	eluding	physiological	phagocytosis.	





As	 bacteria	 chronification	 advances,	 the	 tissue	 promotes	 a	 much	 more	 intense	






of	 infection	 in	 relation	 to	age.	 The	 colonization	occurs	
typically	in	early	ages	with	S.	aureus	and	shifts	towards	
P.	aeruginosa	in	adulthood(26).	(CFF,	2010).	
Figure	 9:	 Cartoon	 displaying	 the	 mechanism	
underlying	 the	 surge	 in	 infections	 in	 CF	patients.	 The	
deficient	 CFTR	 ion	 transport	 cannot	properly	 hydrate	
airway	mucus	by		causing	bacteria	entrapment(34).	
Figure	 11:	 Comparison	 of	 two	 X-ray	 chest	
radiographs.	On	the	left,	a	healthy	pair	of	adult	lungs.	
On	 the	 right,	 the	 lungs	 of	 an	 adult	 with	 advanced	
cystic	 fibrosis.	 Quoting	 the	 original	 pneumologist	
description:	 In	 the	CF	 lungs	we	 can	observe	a	 severe	
bronchiectasis	with	numerous	mucoid	impactations,	a	
retraction	of	both	hilar	 regions	due	 to	tissue	 scarring	






Interestingly,	 this	exacerbated	 local	 inflammation	does	not	only	occur	 in	 response	to	
the	presence	of	microbial	signalling.	CFTR	mutations	alone	have	been	associated	with	
constitutive	 pro-inflammatory	 signalling,	 increased	 oxidative	 stress	 and	 exaggerated	
response	towards	bacteria.	Moreover,	CFTR	is	also	expressed	in	lymphocytes	and	some	






supplementation	 is	 strongly	 recommended	 as	 85%	 of	 CF	 patients	 have	 pancreatic	
insufficiency(21).	Those	supplements	are	directly	obtained	 from	pig	pancreatic	 tissue	







the	 testiscles	 to	 the	 penis,	 resulting	 in	 an	 obstructive	 azoospermia	 that	 cannot	 be	
surgically	 corrected.	 However,	 modern	 fertility	 techniques	 that	 combine	 testicular	
sperm	extraction	and	intracytoplasmic	sperm	injections	can	help	assist	some	cases.			
	






way	 back	when	 genotyping	 of	 CFTR	 or	 new	 born	 screening	 (NBS)	weren’t	 a	 routine	
medical	procedure.	Physicians	had	to	rely	on	diagnosis	based	on	new	born	signs	and	




test	 to	 diagnose	 CF.	 Other	 tests	 include	 secretin	 stimulation	 tests,	 X-rays	 of	 chest,	
upper	GI	and	small	bowel,	lung	function	test	or	the	analysis	of	meconium	fat.		
Figure	 12:	 Snapshot	 of	 2007	 displaying	 the	 age	 of	
diagnosis	 for	 CF	 in	 the	 USA.	 As	 we	 can	 see	 in	 the	
graph,	 66%	 of	 patients	 with	 CF	 were	 diagnosed	 in	













Although	 the	 sweat	chloride	 test	 remains	 the	gold	 standard	 for	CF	diagnosis,	 it	does	
not	always	give	a	clear	and	definitive	diagnosis	as	shown	in	figure	13.	Instead,	modern	
guidelines	for	diagnosing	CF	recommend	that	an	individual	should	meet	all	four	items	
of	 the	 following	criteria(37):	 In	 the	 first	place,	patient	has	 to	present	evident	 clinical	
manifestations	 of	 CF;	 secondly,	 a	 demonstrated	 CFTR	 dysfunction	 as	 measured	 by	
sweat	 chloride	 test;	 thirdly,	 positive	 testing	 in	 NBS;	 finally,	 found	 carrier	 of	 a	 CFTR	
pathogenic	variant	in	a	gene	analysis.	While	CF	diagnosis	is	evident	when	subjects	are	
carriers	 of	 CF-causing	 variants	 on	 both	 alleles,	 further	 extended	 CFTR	 testing	 is	





each	 parent	 to	 pass	 on	 a	 mutated	 copy	 of	 the	 CFTR	 gene.	 Since	 CF	 genotyping	 is	
expensive,	testing	is	often	performed	initially	on	one	parent.	 If	results	 indicate	that	a	
parent	is	a	CFTR	gene	mutation	carrier,	the	other	parent	is	tested	and	the	risk	of	their	
child	 to	 develop	 CF	 is	 calculated	 to	 guide	 parenthood	 decision	making.	 However,	 in	
2016,	only	the	most	common	mutations,	such	as	ΔF508,	are	tested(29,40).		
	
Recently,	 advancements	 in	 genomics,	 especially	 in	 genome	wide	 association	 studies	
(GWAS),	 have	made	possible	 the	discovery	 that	CFTR	genotype	alone	accounts	 for	 a	
modest	 portion	 of	 patient’s	 cystic	 fibrosis	 phenotype	 as	 shown	 in	 figure	 5.	 These	
numerous	 none-CFTR	 genetic	 modifiers,	 regions	 of	 the	 genome	 with	 demonstrated	
linkage	with	 the	 likelihood	 to	 suffer	 severe	 cystic	 fibrosis	 secondary	 diseases,	 play	 a	




Figure	 13:	 Extracted	 from	 the	 2017	
consensus	 guideline	 diagnosis	 scheme	 for	
cystic	 fibrosis(38).	 CFTR	 variants	 genetic	
analysis	positive	results	are	classified	 in	 CF-
causing	 (those	 demonstrated	 to	 cause	 CF),	
mutations	 of	 varying	 clinical	 consequences	
(MVCC;	 mutations	 with	 suspected	 but	 not	
confirmed	 causation)	 and	 undefined	







This	 raises	 an	 obvious	 question,	 if	 modern	 technology	 can	 make	 feasible	 the	
determination	of	cystic	fibrosis	patient’s	predisposition	to	suffer	certain	complications	
or	secondary	diseases,	 in	a	certain	degree,	such	as	cystic	fibrosis-related	diabetes,	by	











life-threatening,	 diseases	 and	 these	 tools	 can	 effectively	 help	 physicians	 tailor	
treatment,	 offering	 personalised	 preventive	 action	 and	 help	 guide	 decision	 making	
regarding	patients	follow	up.	
	
From	 an	 economic	 standpoint,	 the	mean	 annual	 cost	 of	 CF	 treatment	 per	 patient	 is	
15500$(42),	taking	into	account	the	basic	healthcare	principle	“it’s	always	cheaper	to	
prevent	 rather	 than	 threat	 disease”,	 there	 is	 little	 doubt	 that	 implementing	 this	
approach,	 in	a	personalised	medicine	 fashion,	would	certainly	be	cost-effective.	As	a	
mode	of	example,	if	a	certain	patient	has	its	genome	sequenced	and	its	susceptibility	
to	 suffer	 P.	 aeruginosa	 determined,	 physicians	 could	 prescribe	 a	 more	 adequate	
antibiotic	 scheme	 and	 design	 a	 more	 tailored	 follow	 up.	 Conversely,	 if	 a	 patient’s	
degree	 of	 predisposition	 to	 suffer	 cystic	 fibrosis-related	 diabetes	 is	 previously	
determined,	 perhaps	 an	 early	 introduction	 of	 preventive	 hygienic-diet	 actions	 could	





















for	 the	 treatment	 of	 CF	 in	 patients	 2	 years	 of	 age	 and	 older	who	 have	 at	 least	 one	
allele	with	the	following	mutations	in	the	CFTR	gene:	G551D,	G1244E,	G1349D,	G178R,	
G551S,	S1251N,	S1255P,	S549N,	S549R	or	R117H(43–57).	Ion	channel	modulators	aim	
to	 correct	 the	 underlying	 cellular	 defect	 (chloride	 ion	 transport)	 responsible	 for	 CF	
instead	 of	 the	 severity	 of	 symptoms.	 Despite	 the	 classic	 agonist/antagonist	
denomination	often	used	for	receptor	modulators,	Ivacaftor	was	catalogued	as	a	CFTR	
potentiator	 because	 it	 doesn’t	 open	 the	 channel	 on	 it’s	 own,	 instead,	 it	 works	 by	
increasing	the	likelihood	of	CFTR	channel	opening(46).	
	
The	 exact	mechanism	of	 action	 of	 Ivacaftor	 has	 not	 been	 fully	 elucidated.	However,	
recent	research	suggests	that	it	interacts	with	CFTR	in	an	ATP	independent	manner.	In	
addition	 of	 channel	 gating	 promotion	 in	 both	 G551D-CFTR	 and	 wild	 type-CFTR	




was	 first	 studied	 in	 Fischer	 rat	 thyroid	 cells,	 where	 it	 was	 shown	 to	 increase	 both	
chlorine	 transport	 and	open	probability.	 To	 escalate	 experimenting	 towards	 humans	
further,	 a	model	 with	 greater	 similarity	 with	 CF	 lung	 pathogenesis	 was	 used,	 which	





enzymes	 and	 receptors,	 which	 included	 11	 other	 ion	 channels.	 Moreover,	 in	 safety	
pharmacology	studies,	no	adverse	effects	were	observed	in	in	vivo	dog	cardiovascular	
safety	 evaluation,	 neither	 in	 neurological	 and	 respiratory	 functions.	 However,	
gastrointestinal	 studies	 indicated	 a	 remarked	 decrease	 in	motility	 up	 to	 49%	 and	 in	
hERG	 assay	 in	 HEK239	 cells	 Ivacaftor	 	 displayed	 a	 35%	 inhibition	 in	 maximal	
concentrations(47).		
	
In	 pharmacokinetic	 studies,	 Ivacaftor	 metabolism	 after	 oral	 administration,	 occurs	
mainly	through	CYP3A4	resulting	in	two	major	metabolites	M1	and	M6,	with	1/6	and	
1/50	 of	 ivacaftor	 potency	 respectively(43).	 Consequently,	 Ivacaftor	 interacts	with	 all	








In	 clinical	 trials,	 in	 patients	 carrying	 in	 at	 least	 one	 allele	G551D	mutation,	 ivacaftor	
therapy	was	 associated	with	 improved	 forced	expiratory	 volume	 in	1	 second	 (FEV1),	
decreased	risk	of	pulmonary	exacerbation,	increased	quality	of	life,	improved	nutrition	
and	 a	 large	 correction	 in	 the	 typical	 CF	 elevated	 sweat	 chloride	 concentrations(49).	
These	ivacaftor	clinical	trials	findings	were	first	published	back	in	2011	in	NEJM	under	
the	 title	 “A	 CFTR	 potentiator	 in	 patients	 with	 cystic	 fibrosis	 and	 the	 G551D	
mutation”(49),	the	clinical	results	of	which	are	synthetized	in	figure	17.	
	
Figure	 17:	 Changes	 from	 baseline	 of	 different	 clinical	 parameters	 after	 48	 weeks	 of	 treatment	 with	 Ivacaftor	 or	
placebo.	This	clinical	trial	had	213	participants	and	Ivacaftor	was	studied	against	placebo	in	cystic	fibrosis	patients	
with	at	least	one	allele	for	G551D-CFTR	mutation.	Panel	A	shows	the	mean	improvement	in	forced	expiratory	volume	
(FEV1),	which	 ranged	 from	10.6%	to	12.5%.	Panel	B	 shows	 the	 time	 to	 the	 first	pulmonary	exacerbation,	 in	 those	
treated	with	Ivacaftor	the	risk	of	pulmonary	exacerbations	was	55%	lower.	Panel	C	displays	the	effect	that	Ivacaftor	
had	 on	 pulmonary	 function,	 measured	 with	 the	 standard	 Cystic	 Fibrosis	 Questionnaire	 (a	 100-point	 scale	 where	
higher	numbers	indicate	a	lower	effect	of	symptoms	on	the	patient’s	quality	of	life),	where	Ivacaftor	receiving	group	
scored	 8.6	 points	 higher.	 	 Panel	 D	 shows	 the	 change	 in	 weight	 which	 averaged	 a	 3.1kg	 gain	 with	 Ivacaftor.	






The	clinical	benefits	of	 Ivacaftor	were	 truly	 remarkable	 in	clinical	 trials.	Moreover,	 in	
the	extension	studies,	patients	previously	treated	with	Ivacaftor	displayed	a	sustained	
improvement	 in	 FEV1,	 weight	 and	 rate	 of	 pulmonary	 exacerbations	 for	 up	 to	 144	
weeks	of	treatment(50).	However,	there	was	a	lack	of	long-term	data	regarding	critical	
parameters	 such	 as	 mean	 survival	 improvement	 or	 the	 decline	 in	 pulmonary	
transplantation	rates. At	the	same	time,	authorities	noted	that	the	inclusion	criteria	for	
this	 clinical	 trial	 left	out	patients	with	predicted	<40%	FEV1,	 those	with	most	 severe	




treatment	 so	 healthcare	providers	 heavily	 discussed	 its	 inclusion	 in	 their	 services.	 In	
the	USA,	the	cost	of	the	medicine	per	year	of	treatment	is	294.000$(27)	although	the	
manufacturer	offers	both	a	co-pay	assistance	and	free	medicine	program	for	those	in	
most	 need	 who	 can’t	 afford	 the	 treatment(23).	 In	 the	 UK,	 the	 cost	 for	 Ivacaftor	 is	
182.625£	 per	 year.	 To	 asses	 it’s	 cost-effectiveness,	 the	 NHS	 designated	 a	 clinical	
commission	 to	 evaluate	 the	 drug	 and	 calculated	 the	 incremental	 cost	 effectiveness	





of	 other	 ultra-orphan	medicines	 and	 thus	would	 include	 the	drug	 in	 its	 services	 and	
recommend	its	use	for	patients	with	eligible	mutations(29).		(59)	
	
Back	 home,	 in	 Spain,	 each	 Ivacaftor	 package	 containing	 58	 tablets	 costs	 18.720€,	
assuming	the	normal	posology	of	1	tablet	every	12	hours,	the	treatment	costs	a	total	
amount	 of	 244.028€	 per	 year.	 To	 illustrate	 just	 how	 expensive	 this	 treatment	 is	 in	
comparison	to	current	CF	treatments	that	also	reduce	FEV1,	figure	18	was	elaborated.		
	










Posology	 150	mg/12	h	 5	ml/12	h	 2500	U/24	h	















Assessor	 de	 Tractaments	 Farmacològics	 d’Alta	 Complexitat	 (CATFAC)”	 recommended	
the	 drug	 as	 another	 form	 of	 treatment	 for	 CF	 if	 patients	 are	 carriers	 of	 one	 of	 the	
eligible	mutations	and	meet	all	this	specific	criteria(51):		
	
1. Patient’s	 sweat	 chlorine	 concentration	 is	 higher	 than	 60≥	 mmol/L	 or	 is	 a	
demonstrated	carrier	of	2	CF-causing	mutations.	
	
2. Phenotypic	 presence	 of	 sinopulmonary	 disease	 (with	 or	 without	 other	
manifestations	 characteristic	 of	 CF	 such	 as	 pancreatic	 insufficiency,	 sputum	
cultures	positive	for	pathogens	associated	with	CF	or	salt-wasting	syndrome).	
	
3. Patient’s	 predicted	 FEV1	 is	 ≥30%.	 This	 is	 because	 the	 scientific	 evidence	 in	
these	patients	with	predicted	FEV1	<40%	is	currently	lacking.	
	
Furthermore,	 all	 eligible	 patients	 for	 Ivacaftor	 treatment	 require	 an	 individualised	
doctor	 request	authorisation,	approved	by	 the	hospital	medical	director,	and	 further	
evaluation	 and	 authorisation,	 on	 a	 case	 by	 case	 basis,	 by	 CATFAC.	 If	 the	 request	 is	
approved,	 the	 treatment	 will	 require	 a	 specific	 follow	 up	 consistent	 in	 a	 periodic	
treatment	efficacy	evaluation,	with	FEV1	as	the	main	clinical	indicator,	in	months	3,	6,	




current	 scheme	 recommended	 from	 Clinical	 Consortium	 of	 Pharmacogenetics	 for	
Ivacaftor	 treatment	 eligibility	 is	 presented	 in	 figure	 19.	 To	 do	 this	 genetic	
determination,	 there	 are	 currently	 84	 different	 laboratories	 offering	 186	 different	
clinical	 genetic	 tests	 registered	 in	 NCBI’s	 Genetic	 Testing	 Registry	 database.	 From	
those,	100	are	designed	to	sequence	the	entire	coding	region	of	CFTR	gene	and	74	are	




scheme	 for	 Ivacaftor	 eligibility.	 If	 a	
patient	is	proven	to	be	homozygous	for	
Δ508del,	 Ivacaftor	monotherapy	 is	 not	
recommended.	 However,	 if	 he	 is	
heterozygous	 for	 Δ508del	 and/or	
homozygous/heterozygous	 for	 any	 of	
the	 other	 mentioned	 SNP’s	 in	 the	
picture,	 ivacaftor	use	 is	 recommended.	
It	 is	 important	 to	 note	 that	 the	 drug	
costs	 over	 300.000$	 per	 year	 of	
treatment	 and	 currently	 under	 a	 strict	
case	 on	 case	 surveillance,	 so	 patient	
administration	of	 the	drug	 should	only	









situation	 of	 personalised	 medicine	 to	 understand	 it’s	 impact	 in	 our	 future	 disease	
management.		
	




Finally,	 I	 want	 to	 widen	 my	 practical	 knowledge	 in	 genomic	 tools	 available	 to	 the	
general	 public	 to	 improve	 my	 understanding	 of	 genomics.	 In	 order	 to	 achieve	 this	







I	 first	 researched	 about	 personalised	 medicine	 in	 university	 while	 completing	 an	
assignment	 of	 the	 subject	 Research	 in	 pharmaceutical	 biotechnology.	 I	 found	 the	











I	utilised	a	broader	 range	of	 resources	besides	bibliographic	 research.	To	study	CFTR	




















functional	 difference	 of	 performing	 as	 an	 ion	 channel(55).	 CFTR	 structure	 can	 be	
divided	into	five	functionally	different	domains,	shown	in	figures	20,	21	&	22:	 
	
§ Two	 membrane-spanning	 domains	 (MSD1	 and	 MSD2),	 each	 composed	 of	 six	
transmembrane	segments	that	anchor	the	protein	to	the	plasmatic	membrane.		
	
§ Two	 nucleotide-binding	 domains	 (NBD1	 and	 NBD2)	 which	 together	 form	 a	
heterodimer	 complex	 that	 interacts	 with	 nucleotides,	 mainly	 ATP,	 to	 regulate	
chloride	channel	activity	by	regulating	the	opening	and	closing	of	the	MSD’s.		
	
§ The	regulatory	domain	 (R),	which	 is	unique	across	ABC	family,	 that	quantitatively	
regulates	channel	activity	while	activated.		
	
Figure	 20,	 21	 &	 22:	 Comparison	 of	 CFTR	 structure	
depicted	 in	 a	 cartoon	 image(21)	 and	 two	 far	 more	
realistic	 images	 of	 CFTR	 structure	 done	 by	 myself.	 To	
obtain	 these	 images	 I	 used	 Pymol	 software	 and	 the	
available	 data	 of	 dephosphorylated,	 ATP-free	 CFTR	
crystal	structure	obtained	in	a	2017,	not	yet	published,	
study	 (PDB	 5UAK(63)),	 Interestingly,	 in	 this	 protein	
conformation,	 we	 can	 fully	 appreciate	 both	MSD	 6	a-
helices	and	locate	the	R	domain.	To	identify	all	domains	
I	 used	 the	 aminoacidic	 sequences	 available	 in	 Uniprot	
(P13569(64)).	 The	exact	 domain	sequences	are:	MSD1:	
81-103+118-138+195-215+221-241+308-328+331-350;	















description,	 following	 the	 direction	 of	 the	 protein	 primary	 structure,	 the	






glycosylated	 by	 the	 addition	 of	 two	 glycosylated	 groups	 ,	 increasing	 its	weight	 from	
130	 to	 150	 kDa(58).	 With	 the	 help	 of	 chaperone	 molecules,	 such	 as	 Calnexin	 and	
Hsp70,	 the	 protein	 is	 folded,	 acquiring	 resistance	 to	 the	 cellular	 proteases	 and	
transported	to	the	Golgi	apparatus.	This	critical	step	is	apparently	very	inefficient	since	
only	25%	of	the	folded	protein	acquires	effective	resistance	towards	proteases,	making	
the	 transport	 to	 Golgi	 apparatus	 difficult.	 At	 this	 site,	 the	 glycosylated	 groups	 are	
modified	resulting	in	a	mature	170	kDa	protein	which	will	be	transported	to	the	apical	





regulated	 by	 phosphorylation	 of	 Protein	 Kinase	 A	 (PKA)	 dependent	 of	 AMPc.	
Mechanistically,	 to	 activate	 CFTR	 channel	 a	 previous	 preparation	 is	 required,	 which	
consists	 in	the	phosphorylation	of	the	R	domain	and	subsequent	 interaction	with	the	




Although	 CFTR	 was	 initially	 defined	 as	 a	 chlorine	 channel,	 the	 presence	 of	
phosphorylation	 points,	 as	 shown	 in	 figure	 20,	 coupled	 with	 the	 fact	 CFTR	 can	
hydrolyse	 ATP,	 indicate	 that	 the	 protein	 requires	 energy	 to	 perform	 its	 function.	
Therefore,	some	scientists	reclassified	CFTR	as	a	chlorine	active	transporter	instead.		
	
In	 addition	 to	 its	 function	 as	 a	 chlorine	 channel,	 CFTR	 participates	 in	 other	 cellular	






















To	 date,	 over	 2000	 CFTR	 mutations	 have	 been	 identified(25,26,41),	 the	 nature	 of	
which	 is	 very	 diverse	 as	 figure	 23	 demonstrates.	 These	 mutations	 can	 affect	 CFTR	





• Class	 I	mutations	 includes	 nonsense	mutations,	 frame	 shift	mutations	 and	 splice	
site	 mutations	 that	 produce	 premature	 termination	 signals.	 Consequently,	
unstable	 transcripts	 and/or	 aberrant	 proteins	 containing	 deleted	 amino	 acid	
sequences	 are	 formed.	 Such	 proteins	 are	 expected	 to	 be	 degraded	 rapidly,	
producing	a	net	effect	of	low	amount	of	CFTR	on	cell	surface.	
	
• Class	 II	 mutations	 display	 a	 trafficking	 problem	 caused	 by	 a	 misfolded	 or	
improperly	 processed	 CFTR	 protein.	 Under	 these	 circumstances,	 upon	 entrance	
into	 the	 endoplasmatic	 reticulum,	 most	 protein	 is	 degraded	 by	 cellular	 quality	
controls.	 A	 classic	 example	 of	 this	 group	 is	 the	 Δ508del	 mutation,	 a	 sequence	





with	 the	 activating/gating	 of	 the	 channel.	Most	 of	 these	mutations	 are	 found	 in	
NBD	and	interfere	with	the	binding	of	ATP	to	these	domains	or	with	the	stimulation	
of	 the	 channel	by	ATP,	 resulting	 in	 a	decreased	net	 chloride	 transport	 activity	of	














• Class	 IV	mutations	have	affected	amino	acids	 in	MSD1,	 located	in	the	pore	of	the	
channel.	 Consequently,	 although	 the	 ATP	 binding	 and	 the	 quantity	 of	 CFTR	 on	




















However,	 the	genetic	 classification	discussed	above	 is	 impractical	 in	a	 clinical	 setting	
scenario.	Instead,	a	simpler	classification	is	used	to	improve	CF	patient	communication.	
Shown	 in	 figure	 25,	 CFTR	 mutations	 variants	 are	 classified	 into	 3	 groups	 (normal,	




Figure	 24:	 Map	 displaying	 the	
mutations	 nature	 and	 location	
across	 the	27	exons,	26	 introns	
and	 other	 genetic	 regions	 that	
conform	 CFTR	 gene.	 (Image	
source:	 Cystic	 fibrosis	mutation	
database(25))	
Figure	 25:	 The	 phenotype	 of	 CF	
depends	on	the	genetic	 dotation	of	
both	 CFTR	 gene	 alleles.	 Depending	
on	the	exact	combination	of	alleles,	
patients	will	 display	a	more	or	 less	
aggressive	 form	 of	 CF.	 As	 seen	 in	
the	 image,	 patients	 with	 only	 one	
pathogenic	allele	might	only	display	
a	 mild	 form	 of	 CF	 whereas	
homozygous	 individuals	 for	 severe	
CF-causing	 mutations	 display	 seve	








Using	 the	 genomic	data	 from	differentially	 expressed	genes	between	normal	 and	CF	
human	 cells	 from	 a	 recent	 gene	 expression	 study	 where	 researchers	 compared	 the	
transcriptome	of	colon	epithelial	cells	between	healthy	participants	and	cystic	fibrosis	
patients	 I	 generated	 figure	 26.	 In	 this	 network	 of	 genes,	 each	 sphere	 represents	 a	
single	 gene	 with	 its	 size	 correlated	 with	 the	 magnitude	 of	 differential	 expression	
between	the	two	groups	and	each	connection	between	genes	(nodes)	accounts	for	a	
predicted	 protein-protein	 interaction.	 The	 quantity	 of	 nodes	 and	 the	 degree	 of	
clustering	 in	 these	 networks	 give	 scientists	 insight	 of	 the	 nature	 and	 severity	 of	
alteration	 that	 CF	 causes	 in	 gene	 expression.	 In	 this	 particular	 network,	 we	 can	
appreciate	2	clusters	of	proteins	connected	via	several	nodes.	As	demonstrated	in	the	
original	 study,	 the	protein	expressed	by	ACTB	gene	 (ß-actin),	 highlighted	 in	 red,	was	










position	 551	 of	 CFTR	 protein	 during	 translation(34,55).	 It	 is	 a	 class	 III	 mutation,	 a	
missense,	that	causes	a	severe	reduction	in	channel-open	probability	of	CFTR(54)	and	
is	 associated	 with	 a	 severe	 CF	 phenotype	 characterized	 for	 a	 marked	 pulmonary	
dysfunction	 and	 pancreatic	 insufficiency(64).	 Of	 the	 approximately	 70,000	 cases	 of	
cystic	fibrosis	worldwide,	3-4%	are	carriers	of	the	G551D	mutation,	making	it	the	third	
most	prevalent	CF	mutation(23,65).	The	allele	frequency	of	G551D	in	the	whole	world	
population	 is	 very	 low	 and	 highly	 varies	 with	 ethnicity/race,	 with	 values	 between	
0.02069%	among	caucasians	and	0.0013%	in	middle	eastern	populations(54).		
	
Figure	26:	 The	microarray	data	 I	 used	 to	 obtain	
this	network	was	extracted	from	the	study	“Gene	
expression	 in	 rectal	 epithelia	 of	 cystic	 fibrosis	
patients”(63),	 incorporated	 in	 the	 public	 GEO	
Datasets	 Catalogue	 (GSE15568	 entry).	 The	 data	
of	 this	study	was	submitted	to	GEOR2R	analysis,	
next,	 the	 top	 50	 genes	 from	 the	 pool	 of	 146	
genes	 list	 encountered,	 whose	 expression	 was	
significantly	different	between	the	2	groups,	was	
adjusted	 for	 P	 value,	 and	 was	 submitted	 to	 the	








To	 understand	 the	 changes	 that	 G551D	 causes	 in	 CFTR	 structure,	 we	 must	 first	
acknowledge	the	fact	that	when	both	NBD	domains	dimerise,	in	a	head	to	tail	manner,	




of	both	ATBP	pockets	 in	 this	 interaction	 is	 critical	 for	 the	ATP-dependent	opening	of	




sequences,	 and	 Glycine551,	 located	 on	 NBD1’s	 ATBP2	 pocket,	 is	 one	 of	 them.	
Mechanistically,	 the	G551D	mutation	difficults	 the	ability	of	ATP	 to	bind	 into	ATBP2,	
completely	eliminating	the	ability	of	ATP	to	increase	the	opening	rate	of	CFTR(67).	To	







the	 experimental	 5UAK	 crystal	 structure	 data,	 I	 proceeded	 to	 locate	 and	 highlight	
where	Gly551	is	located,	shown	in	figure	28,	demonstrating	its	location	is	in	the	outer	
surface	 of	 the	 region	 of	 NBD1	 domain	 that	 dimerises	 with	 NBD2.	 This	 observation,	
taking	into	account	that	Gly551	participates	in	the	formation	of	ATBP2,	the	change	of	
this	 glycine	 for	 an	 aspartic	 acid,	 a	much	more	 acidic	 and	 bigger	 in	 volume	 residue,	









Restoring	 the	 mutant	 CFTR	 dysfunction	 of	 G551D	 was	 thought	 to	 be	 possible	 by	
identifying	and	correcting	the	specific	cause	that	changes	total	CFTR	activity,	which	as	
explained	 before,	 depends	 on	 the	 total	 amount	 of	 CFTR	 available	 at	 the	 plasma	




However,	 as	easy	as	 it	 sounds,	 strategies	aiming	 to	 restore	 function	 to	mutant	CFTR	
date	back	 to	 the	90s.	Both	pharmacological	 and	nonpharmacological	 strategies	have	
been	 designed.	 Notable	 examples	 include	 treatment	 of	 cells	 with	 co-chaperone	
molecules,	 suppression	 of	 premature	 termination	 codons	 with	 aminoglycosides	 and	
drug	 based	 treatments	 with	 Curcumin,	 Misglustat	 or	 Ataluren(22).	 The	 latter,	 is	
currently	in	phase	III	clinical	trials(26).	
	
Until	 Ivacaftor,	 first	 approved	 only	 for	 G551D	 mutation	 on	 2012,	 there	 wasn’t	
commercialised	 any	 agent	 capable	 of	 reverting	mutant	 CFTR	 dysfunction.	 Therefore,	
Ivacaftor	was	a	huge	breakthrough	in	CF	therapy	and	a	ray	of	hope	for	cystic	fibrosis	








conducted	with	both	 viral	 and	non-viral	 gene	 vectors	 trying	 to	 insert	 in	 the	 genome	
WT-CFTR	and	all	of	them	failed	to	show	sustained	clinical	benefits(68).	However,	with	
the	recent	developments	in	CRISPR/Cas9	technology,	the	possibility	to	cure	any	type	of	
cystic	 fibrosis	mutation	 is	 gaining	 strength.	With	 this	 technique,	 the	 scenario	where	




structure	 of	 CFTR	 (PDB	 5UAK(63)).	 I	
located	 Gly551	 and	 subsequently,	
disabled	 surface	 display	 for	
aminoacids	within	 6Å	diameter	 from	
Gly551.	 In	 the	 image	 we	 can	 fully	
appreciate	 how	 Gly551	 is	 located	 in	
the	 outermost	 part	 of	 NBD1	 (green)	
that	 faces	 NBD2	 (pink),	 supporting	
the	 hypothesis	 that	 G551D	mutation	








In	 order	 to	 be	 able	 to	 design	 the	 probes	 to	 test	 Ivacaftor	 eligibility	 I	 consulted	 the	
current	EMA	approved	eligible	mutations(48).	The	methodology	I	used,	after	knowing	
which	mutations	the	test	should	account	for,	consisted	of	a	PharmGKB	research	of	said	





finally	 obtain	 the	 final	 DNA	 molecule	 that	 will	 be	 used	 as	 probes	 and,	 if	 desired,	




Figure	29:	 To	determine	 if	 a	patient	 is	 homozygous	 for	a	 certain	 variant,	 say	 [G551D/G551D],	 hybridization	must	
only	occur	only	with	the	G551D	pathogenic	probe	(light	reddish).	On	the	other	hand,	a	heterozygous	genotype	such	
as	[Δ508/S1255P]	would	display	in	the	assay	with	hybridization	occuring	in	both	pathogenic	probes.	If	no	pathogenic	
probe	hybridizes	 in	 the	 test,	patient	might	 still	 be	 carrier	of	other	mutations	CF-causing	mutations.	 The	predicted	



























































13	 mutations	 eligible	 for	 Ivacaftor	 treatment.	 On	 the	 other	 hand,	 for	 the	 not	
pathogenic	ones,	highlighted	 in	green,	a	minimum	of	9	probes	are	 required	because	






sample,	 the	 patient’s	 DNA	 is	 extracted.	 Then,	 the	 CFTR	 gene	 is	 amplified	 by	 PCR	
techniques,	 fragmented	 and	 labelled.	 The	 next	 step	 is	 a	 hybridization	 of	 the	 PCR	







However,	 in	practice,	patients	 first	 should	 test	 for	Δ508del	and	only	proceed	 further	
with	my	pharmacogenetic	chip	if	not	found	Δ508del/	Δ508del	or	Δ508del/WT	because	
Amplichip	tests	are	quite	expensive,	with	a	price	between	600-1200€.	This	preliminary	
mutation	 test	 is	 available	 all	 over	 the	 world	 and	 easily	 identifies	 CF	 patients	 with	
genotypes	 Δ508del/Δ508del	 or	 WT/Δ508del,	 which	 are	 not	 candidate	 for	 Ivacaftor.	






Figure	 30:	 On	 the	 right,	 Imegen’s	 kit	 to	 sequence	 by	 capillary	
electrophoresis	 (Sanger	sequencing)	the	whole	CFTR	gene.	This	kit	
includes	 all	 needed	 reagents	 to	 perform	 the	 amplification	 of	 all	
coding	 regions	 and	 the	 primers	 for	 the	 sequencing	 reactions.	 On	
the	 bottom,	 the	 same	 company	 offers	 different	 test	 services	 for	








• With	 the	 current	 advancements	 in	 bioinformatics	 and	 genomic	 technologies,	
personalised	medicine	has	the	potential	to	explore	the	causes	of	the	variability	 in	




• Despite	 having	 been	 studied	 for	many	 decades	 and	 being	 a	monogenic	 disease,	
cystic	 fibrosis	 is	 a	 very	 complex,	 chronic,	 life-threatening	 disorder	 the	 clinical	




• Even	 though	cystic	 fibrosis	 is	 the	most	 common	and	widespread	genetic	disease,	
the	exact	reason	to	explain	its	prevalence	has	not	been	fully	elucidated	yet.	
	









• The	 total	 CFTR	 activity	 is	 determined	 by	 CFTR	 genotype	 which	 results	 from	 the	
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Annex	1	
	
The	current	official	doctor	request	form	file	to	request	Ivacaftor	treatment	in	Catalonia	
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